NASDAQ: NCNANucana PLC Stock
$1.95-0.02 (-1.02%)
Updated Jun 10, 2026
NCNA Price
$1.95
Fair Value Price
N/A
Market Cap
$0.00
52 Week Low
$1.33
52 Week High
$33.62
P/E
N/A
P/B
0x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$40.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.23
Operating Cash Flow
-$14M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NCNA Overview
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NCNA's potential to beat the market
- NCNA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NCNA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important NCNA news, forecast changes, insider trades & much more!
NCNA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NCNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NCNA's cash burn is expected to be positive in the next year ($1.99M), after accounting for decreasing cash burn (86.05%)
Interest Coverage Financials
NCNA's short-term assets ($33.20M) exceed its short-term liabilities ($6.06M)
Short-term Liabilities Financials
NCNA's short-term assets ($33.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more NCNA due diligence checks available for Premium users.
Valuation
NCNA fair value
Fair Value of NCNA stock based on Discounted Cash Flow (DCF)
Price
$1.95
Fair Value
$1.48
Overvalued by
31.91%
NCNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
18.33x
Market
14.77x
NCNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
4.71x
NCNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
NCNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$36.7M
Liabilities
$6.9M
Debt to equity
0.23
NCNA's short-term assets ($33.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NCNA's short-term assets ($33.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NCNA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NCNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$96.0k
Financing
-$9.3k
NCNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NCNA vs Biotech Stocks
Nucana Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.